Federal Circuit Affirms Court Ruling That Generic Trizivir Didn’t Infringe

In a judgment that wasn’t accompanied by any opinion, the U.S. Court of Appeals for the Federal Circuit recently affirmed without comment a 2013 ruling from a Delaware federal district court that allowed Lupin Pharmaceuticals Inc. to launch a generic version of ViiV Healthcare’s AIDS treatment Trizivir (VIIV Healthcare UK, Ltd. v. Lupin, Ltd.).

The Federal Circuit, in an unsigned opinion, affirmed the lower court’s ruling that Lupin’s generic wouldn’t infringe a patent covering the drug 12 PLIR 7, 1/3/14.

In December 2013, Judge Richard G. Andrews of the U.S. District Court for the District of Delaware ...